Award recognizes Bigfoot’s commitment to delivering innovative technologies that simplify the complexities of diabetes management for people living with insulin-requiring diabetes MILPITAS, Calif.–(BUSINESS WIRE)–Bigfoot Biomedical (Bigfoot), a leader in developing intelligent connected injection support systems, has been selected as one of Fast Company’s 2023 “World’s Most Innovative Companies” in the medical device category. Fast Company … [Read more…]

HENDERSON, Nev.–(BUSINESS WIRE)–P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, announces that Dr. Amir Bacchus, co-founder and Chief Medical Officer, will be participating in a fireside chat at the upcoming Jefferies Value-Based Care Summit in Miami Beach, FL on March 13, 2023. Dr. Bacchus will … [Read more…]

NDA Priority Review PDUFA Date for ADX-2191 for the Treatment of Primary Vitreoretinal Lymphoma is June 21, 2023 NDA PDUFA Date for Reproxalap for the Treatment of Dry Eye Disease is November 23, 2023 Top-Line Results from the Phase 3 INVIGORATE-2 Trial of Reproxalap in Allergic Conjunctivitis Expected in the First Half of 2023 Top-Line … [Read more…]

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Eric Shaff, President and Chief Executive Officer of Seres Therapeutics, will provide a corporate presentation at the Oppenheimer 33rd Annual Healthcare Conference on Wednesday, March 15, 2023 at 8:40 a.m. ET. An audio webcast of the presentation will be available … [Read more…]

Results showed that IMFINZI-based treatment before and after surgery significantly increased the time patients live without recurrence or progression events WILMINGTON, Del.–(BUSINESS WIRE)–Positive high-level results from a planned interim analysis of the AEGEAN Phase III, placebo-controlled trial showed that treatment with AstraZeneca’s IMFINZI® (durvalumab) in combination with neoadjuvant chemotherapy before surgery and as adjuvant monotherapy … [Read more…]

HOUSTON–(BUSINESS WIRE)–Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing multiple therapeutic platforms intended to enhance Treg function, including biologics and cell therapies, today announced it will host a conference call to present clinical data of Coya’s proprietary investigational biologic combination, COYA 302, in patients with Amyotrophic Lateral Sclerosis (ALS), … [Read more…]

REDWOOD CITY, Calif. & BOSTON–(BUSINESS WIRE)–Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that Chen Schor, President and Chief Executive Officer, and Nick Harvey, Chief Financial Officer, will participate in the 2023 Jefferies Biotech on the Bay Summit being held … [Read more…]

Robin Leopold, EVP and Head of Human Resources at JPMorgan Chase, Joins LetsGetChecked Board of Directors NEW YORK–(BUSINESS WIRE)–LetsGetChecked, a global healthcare solutions company, announced today the appointment of Robin Leopold, Executive Vice President and Head of Human Resources at JPMorgan Chase, and a member of the company’s Operating Committee, to its Board of Directors. … [Read more…]

Revenue grew 3.5x YoY, to $1.11 billion, exceeding guidance Cost of Care Delivery (COCD) Margin in the U.K. already profitable1, with U.S. Clinical services also expecting COCD profitability in early 2023 Key U.S. VBC contracts delivered profitable Medical Margins2 in their first year Monthly Adjusted EBITDA of $(16.3) million for Q4 2022 beating guidance of … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “United States Specialty Generics Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027” report has been added to ResearchAndMarkets.com’s offering. The United States specialty generics market size reached US$ 23.6 Billion in 2021. Looking forward, the publisher expects the market to reach US$ 43.1 Billion by 2027, exhibiting a CAGR of 10.56% … [Read more…]